Jane S. Ricciuti, RPh, MS


February 12, 2004

In This Article


The US Food and Drug Administration (FDA) approved Symbyax (olanzapine and fluoxetine HCl) for use as a combination product in the treatment of depressive episodes associated with bipolar disorder. Also approved by the FDA was the use of Zyprexa (olanzapine) in the long-term treatment of bipolar I disorder.

Eloxatin (oxaliplatin) injection in combination with infusional 5-fluorouracil (5-FU) and leucovorin (LV) was approved for the treatment of patients previously untreated for advanced colorectal cancer.

This month's column reviews FDA new product approvals and labeling changes for:


  • Symbyax (olanzapine and fluoxetine HCl) Capsules

Anti-infective Agents

  • Zithromax (azithromycin) Oral Suspension and Tablets

Antineoplastic Agents

  • Eloxatin (oxaliplatin) Injection

  • Faslodex (fulvestrant) Injection

Antipsychotic Agents

  • Seroquel (quetiapine fumarate) Tablets

  • Zyprexa (olanzapine) Tablets

Cardiovascular Agents

  • Norvasc (amlodipine besylate) Tablets